The deal prepares for a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

A new study has compared Wegovy and Zepbound head-to-head in their ability to treat obesity. People taking Eli Lilly’s ...

Thai healthcare solutions company Zuellig Pharma has announced that Mounjaro (tirzepatide), Eli Lilly’s (NYSE: LLY) ...

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

Obstructive sleep apnea severity measured via apnea-hypopnea index decreased among patients receiving AD109, an oral combination drug, for 26 weeks, according to phase 3 SynAIRgy trial topline results ...

Innovent announces phase 3 study of mazdutide in Chinese adults with overweight or obesity (GLORY-1) published in the NEJM: San Francisco, US Tuesday, May 27, 2025, 11:00 Hrs [IST ...

BANGKOK, THAILAND - Media OutReach Newswire - 27 May 2025 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounja ...

Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounjaro® (tirzepatide), the innovative obesity and diabetes medicine developed by Eli Lilly and Company, will be ...

Veru's pivot with enobosarm: groundbreaking Phase 2b results enhance GLP-1 therapy outcomes. A positive launch could yield ...